1. Home
  2. BEAT vs AYTU Comparison

BEAT vs AYTU Comparison

Compare BEAT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartbeam Inc.

BEAT

Heartbeam Inc.

HOLD

Current Price

$0.49

Market Cap

31.6M

Sector

Technology

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.28

Market Cap

27.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAT
AYTU
Founded
2015
N/A
Country
United States
United States
Employees
17
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.6M
27.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
BEAT
AYTU
Price
$0.49
$2.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$5.63
$9.33
AVG Volume (30 Days)
581.0K
23.1K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
$315.97
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$0.48
$1.65
52 Week High
$4.00
$3.07

Technical Indicators

Market Signals
Indicator
BEAT
AYTU
Relative Strength Index (RSI) 34.10 57.95
Support Level N/A $2.08
Resistance Level $0.79 $2.31
Average True Range (ATR) 0.04 0.08
MACD 0.00 0.02
Stochastic Oscillator 8.86 83.33

Price Performance

Historical Comparison
BEAT
AYTU

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: